Osimertinib received FDA approval on November 13, 2015 [1]. It was approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have specific epidermal growth factor receptor (EGFR) mutations [1].
What specific EGFR mutations does Osimertinib target?
Osimertinib is indicated for patients with EGFR exon 19 deletions or EGFR exon 21 L858R substitution mutations [1].
How does Osimertinib work?
Osimertinib is a type of targeted therapy known as an EGFR tyrosine kinase inhibitor (TKI). It works by blocking the activity of abnormal EGFR proteins that promote cancer cell growth [2]. It is designed to be effective against both the initial EGFR mutations and the T790M resistance mutation [2].
When does Osimertinib's patent expire?
Patent information for drugs can be complex and subject to change. For the most current and detailed information on Osimertinib's patent expiry, it is recommended to consult resources like DrugPatentWatch.com [3].
Who manufactures Osimertinib?
Osimertinib is manufactured by AstraZeneca [1].
What are the potential side effects of Osimertinib?
Common side effects reported for Osimertinib include diarrhea, rash, dry skin, stomatitis, and fatigue [1]. More serious side effects can include interstitial lung disease, heart problems, and severe skin reactions [1].
How does Osimertinib compare to other EGFR inhibitors?
Osimertinib is considered a third-generation EGFR TKI. Previous generations of EGFR inhibitors, such as gefitinib and erlotinib, were also used for EGFR-mutated NSCLC but often faced challenges with resistance, particularly the T790M mutation. Osimertinib was developed to overcome this resistance mechanism [2].
What is the regulatory status of Osimertinib outside the US?
Following its FDA approval, Osimertinib has also been approved by other regulatory agencies worldwide for similar indications [2].
Where can I find more detailed information on Osimertinib's approval and patent status?
For comprehensive details on Osimertinib's FDA approval, indications, and patent exclusivity information, DrugPatentWatch.com is a valuable resource [3].
What is the clinical trial data supporting Osimertinib's approval?
The FDA approval was based on clinical trials demonstrating Osimertinib's efficacy in patients with EGFR-mutated metastatic NSCLC. These trials showed significant improvements in progression-free survival [2].
Are there any ongoing clinical trials for Osimertinib?
Research and clinical trials for Osimertinib continue to explore its use in different settings of NSCLC, including earlier stages of the disease and in combination with other therapies [2].
What are the implications of Osimertinib for patients with EGFR-mutated NSCLC?
Osimertinib has offered a significant advancement for patients with specific EGFR mutations, providing an effective treatment option that addresses common resistance mechanisms encountered with earlier therapies [2].
*
**Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-packages
[2] https://www.astrazeneca.com/
[3] https://drugpatentwatch.com/